BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2023-09

185 industry Phase 2/3 trial readout(s) and 35 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

2023-10 →

FDA decision events

DateEventStatusCompanyDrugSource
2023-09-06FDA approvalapprovedPFIZER PFEIBRANCEApproved 2023-09-06: IBRANCE (NDA207103 SUPPL17)
2023-09-06FDA approvalapprovedPFIZER PFEIBRANCEApproved 2023-09-06: IBRANCE (NDA212436 SUPPL5)
2023-09-06FDA approvalapprovedEMD SERONO INCBAVENCIOApproved 2023-09-06: BAVENCIO (BLA761049 SUPPL15)
2023-09-07FDA approvalapprovedPF PRISM CVXALKORIApproved 2023-09-07: XALKORI (NDA217581 ORIG1)
2023-09-07FDA approvalapprovedPF PRISM CVXALKORIApproved 2023-09-07: XALKORI (NDA202570 SUPPL36)
2023-09-08FDA approvalapprovedAYRMID PHARMAAPHEXDAApproved 2023-09-08: APHEXDA (NDA217159 ORIG1)
2023-09-12FDA approvalapprovedSANDOZCYCLOPHOSPHAMIDEApproved 2023-09-12: CYCLOPHOSPHAMIDE (NDA217150 ORIG1)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA022277 SUPPL18)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA022277 SUPPL19)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA022277 SUPPL17)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA021029 SUPPL37)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA021029 SUPPL38)
2023-09-14FDA approvalapprovedMERCK SHARP DOHME MRKTEMODARApproved 2023-09-14: TEMODAR (NDA021029 SUPPL36)
2023-09-15FDA approvalapprovedACADIA PHARMS INC ACADNUPLAZIDApproved 2023-09-15: NUPLAZID (NDA207318 SUPPL12)
2023-09-15FDA approvalapprovedGENZYME CORPNEXVIAZYMEApproved 2023-09-15: NEXVIAZYME (BLA761194 SUPPL5)
2023-09-15FDA approvalapprovedGLAXOSMITHKLINEOJJAARAApproved 2023-09-15: OJJAARA (NDA216873 ORIG1)
2023-09-15FDA approvalapprovedACADIA PHARMS INC ACADNUPLAZIDApproved 2023-09-15: NUPLAZID (NDA210793 SUPPL9)
2023-09-19Complete response letterapproved sinceARS Pharmaceuticals, Inc. SPRYNeffy (ARS-1, epinephrine nasal spray), 2 mg/0CRL 2023-09-19: ARS Pharmaceuticals, Inc. NDA 214697 (Neffy (ARS-1, epinephrine nasal spray), 2 mg/0)
2023-09-21FDA approvalapprovedBOEHRINGER INGELHEIMJARDIANCEApproved 2023-09-21: JARDIANCE (NDA204629 SUPPL40)
2023-09-22Complete response letterapproved sinceBotanix SB Inc.sofpironium bromideCRL 2023-09-22: Botanix SB Inc. NDA 217347 (sofpironium bromide)
2023-09-22FDA approvalapprovedFABRE KRAMEREXXUAApproved 2023-09-22: EXXUA (NDA021164 ORIG1)
2023-09-22FDA approvalapprovedSAPTALIS PHARMSLIKMEZApproved 2023-09-22: LIKMEZ (NDA216755 ORIG1)
2023-09-25FDA approvalapprovedFAMYGEN LIFE SCIRYZUMVIApproved 2023-09-25: RYZUMVI (NDA217064 ORIG1)
2023-09-26FDA approvalapprovedPF PRISM CVBOSULIFApproved 2023-09-26: BOSULIF (NDA203341 SUPPL25)
2023-09-26FDA approvalapprovedPF PRISM CVBOSULIFApproved 2023-09-26: BOSULIF (NDA217729 ORIG1)
2023-09-27FDA approvalapprovedTAKEDA PHARMS USA TAKENTYVIOApproved 2023-09-27: ENTYVIO (BLA761133 ORIG1)
2023-09-28Complete response letterapproved sinceEli Lilly and Company LLYlebrikizumab injectionCRL 2023-09-28: Eli Lilly and Company BLA 761306 (lebrikizumab injection)
2023-09-28FDA approvalapprovedAMICUS THERAP USPOMBILITIApproved 2023-09-28: POMBILITI (BLA761204 ORIG1)
2023-09-28FDA approvalapprovedAMICUS THERAP USOPFOLDAApproved 2023-09-28: OPFOLDA (NDA215211 ORIG1)
2023-09-29Complete response lettercomplete responseGalderma R&D, LLCCRL 2023-09-29: Galderma R&D, LLC BLA 761311
2023-09-29FDA approvalapprovedNOVO NVORIVFLOZAApproved 2023-09-29: RIVFLOZA (NDA215842 ORIG1)
2023-09-29FDA approvalapprovedBAXTER HLTHCARE CORP BAXVASOPRESSIN IN SODIUM CHLORIDE 0.9%Approved 2023-09-29: VASOPRESSIN IN SODIUM CHLORIDE 0.9% (NDA217569 ORIG1)
2023-09-29FDA approvalapprovedBIOGEN MA BIIBTOFIDENCEApproved 2023-09-29: TOFIDENCE (BLA761354 ORIG1)
2023-09-29FDA approvalapprovedCYCLOMEDICATECHNEGAS KITApproved 2023-09-29: TECHNEGAS KIT (NDA022335 ORIG1)
2023-09-29FDA approvalapprovedBAXTER HLTHCARE CORP BAXMICAFUNGIN IN SODIUM CHLORIDE 0.9%Approved 2023-09-29: MICAFUNGIN IN SODIUM CHLORIDE 0.9% (NDA216142 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2023-09P1/P2Philogen S.p.A.NCT02957019 A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory DiffDiffuse Large B-cell Lymphoma (DLBCL)terminated6
2023-09 est.P1/P2RHEACELL GmbH & Co. KGNCT03549299 Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCDLimbal Stem Cell Deficiencyunknown16
2023-09 est.P1/P2Shanghai JMT-Bio Inc.NCT04255576 Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of BoneGiant Cell Tumor of Boneunknown139
2023-09 est.P3UCB Biopharma SRLNCT04643483 A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's DiseaseCrohn's Diseasewithdrawn
2023-09 est.P2Axcella Health, IncNCT04880187 Safety, Tolerability, and Efficacy of AXA1125 in NASH With FibrosisNon Alcoholic Steatohepatitis (NASH)unknown273
2023-09 est.P2Sorrento Therapeutics, Inc.NCT04885972 Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee OsteoarthritisOsteoarthritis, Knee; Knee Osteoarthritis; Knee Pain Chronicunknown124
2023-09 est.P2/P3Shanghai Miracogen Inc.NCT04924699 A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerAdvanced Breast Cancer; Metastatic Breast Cancerunknown350
2023-09 est.P2NanoMab Technology (UK) LimitedNCT04992715 PD-L1 Expression in Lung CancerNon-Small Cell Lung Cancerunknown15
2023-09 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT05105464 A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid TumorsLocally Advanced Unresectable Carcinomaunknown97
2023-09 est.P2Lallemand Health SolutionsNCT05198700 The Effect of Probiotics on Symptoms of Infantile ColicColicwithdrawn
2023-09 est.P3Xiamen LP Pharmaceutical Co., LtdNCT05199818 Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MECChemotherapy-induced Nausea and Vomitingunknown328
2023-09 est.P2Saol Therapeutics IncNCT05311215 Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb SpasticitySpasticityunknown32
2023-09 est.P2Cardurion Pharmaceuticals, Inc.NCT05312021 Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection Fractionwithdrawn
2023-09 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT05528679 A Phase II Study of 610 in Participants With Severe Eosinophilic AsthmaAsthmaunknown120
2023-09 est.P3EyePoint Pharmaceuticals, Inc. EYPTNCT05550350 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract SurgeryCataractwithdrawn
2023-09 est.P3EyePoint Pharmaceuticals, Inc. EYPTNCT05550363 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)Cataractwithdrawn
2023-09 est.P1/P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT05588908 A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutAcute Goutunknown120
2023-09 est.P2AceragenNCT05641298 Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary ExacerbationsCystic Fibrosis; Cystic Fibrosis Pulmonary Exacerbationwithdrawn
2023-09 est.P2Tosk, Inc.NCT05658016 Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690Mucositisunknown24
2023-09 est.P2Tosk, Inc.NCT05669521 Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690Mucositisunknown24
2023-09 est.P2/P3Frontier Biotechnologies Inc. ULCCNCT05675072 Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19unknown1336
2023-09-01 est.P1/P2Takeda TAKNCT04260009 Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, InflammatorAnaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma; Inflammatory Myofibroblawithdrawn
2023-09-01 est.P1/P2EMD Serono Research & Development Institute, Inc.NCT04655183 Study of M4344 in Combination With NiraparibAdvanced Solid Tumor; Breast Cancerwithdrawn
2023-09-01P2Stayble TherapeuticsNCT04673461 Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back PainDiscogenic Paincompleted110
2023-09-01P3Palatin Technologies, Inc PTNNCT05201170 A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry EyeDry Eye; Dry Eye Syndromescompleted575
2023-09-01 est.P2/P3Ocugen OCGNNCT05258669 Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy AdultsCOVID-19unknown400
2023-09-01P1/P2Santiste Medical Inc.NCT05348343 Activated PRP for Treatment of Androgenetic AlopeciaAndrogenetic Alopeciacompleted17
2023-09-01 est.P1/P2Shanghai Henlius BiotechNCT05390528 A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or LymphoAdvanced Tumors; Lymphoma; Metastatic Tumorsunknown30
2023-09-01P2Incyte Corporation INCYNCT05593445 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen SclerosusLichen Sclerosuscompleted61
2023-09-01 est.P3Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdNCT05679492 Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19COVID-19withdrawn
2023-09-01P2Guangdong Longchuangji Pharmaceutical Co., Ltd.NCT07418918 Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb)Bacterial Vaginosiscompleted66
2023-09-04P3Kyntra Bio KYNBNCT04419558 Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosisterminated372
2023-09-04P2Bausch Health Americas, Inc.NCT05098028 Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseSickle Cell Diseasecompleted44
2023-09-04P1/P2Eisai Co., Ltd.NCT05278663 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus ParticipantsLupus Erythematosus, Systemiccompleted26
2023-09-04P3Jiangsu Rec-Biotechnology Co., Ltd.NCT05398848 Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)COVID-19completed7623
2023-09-04P3ModernaTX, Inc.NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsSeasonal Influenzacompleted6102
2023-09-04P3Takeda TAKNCT05543187 A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)Progressive Familial Intrahepatic Cholestasis (PFIC)completed5
2023-09-05P1/P2AC Immune SA ACIUNCT04445831 A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseAlzheimer's Disease; Cognitive Impairment; Tauopathies; Mild Cognitive Impairment; Dementia; Brain Dcompleted57
2023-09-05P2Aclaris Therapeutics, Inc. ACRSNCT05279417 ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)Rheumatoid Arthritiscompleted251
2023-09-05P2Sunshine Lake Pharma Co., Ltd. SBFMNCT05397379 A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic SteatohepatitisNon-Alcoholic Steatohepatitiscompleted68
2023-09-05P2MoonLake Immunotherapeutics AG MLTXNCT05640245 Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisArthritis, Psoriaticcompleted207
2023-09-06P2ActelionNCT01093326 Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisMultiple Sclerosiscompleted353
2023-09-06P2Genzyme, a Sanofi CompanyNCT02004704 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencySphingomyelin Lipidosiscompleted25
2023-09-06P2Palisade Bio PALINCT02836470 A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionIleus; Post-Operative Adhesionscompleted112
2023-09-06P3Alkermes, Inc. ALKSNCT03201757 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831Schizophrenia; Schizophreniform Disorder; Bipolar I Disordercompleted523
2023-09-06P1/P2Faron Pharmaceuticals LtdNCT03733990 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)Cancercompleted216
2023-09-06P2DurectNCT04563026 A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic Hepatitiscompleted307
2023-09-06P3Zydus Lifesciences LimitedNCT05283837 A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)Metastatic Breast Cancercompleted268
2023-09-06P3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT05846568 Study to Evaluate GR1801's Efficacy and SafetyRabies Post-exposure Prophylaxiscompleted1200
2023-09-07P3AstraZeneca AZNNCT03519971 Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerNon-Small Cell Lung Cancercompleted328
2023-09-07P1/P2Shasqi, Inc.NCT04106492 Phase 1/2a Study of SQ3370 in Patients With Advanced Solid TumorsCancerterminated53
2023-09-07P2Calcilytix Therapeutics, Inc., a BridgeBio companyNCT04581629 Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1)completed13
2023-09-07P2OliPass CorporationNCT05216341 Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee JointOsteoarthritiscompleted134
2023-09-07P1/P2Merck Sharp & Dohme LLC MRKNCT05394350 A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)Advanced Solid Tumorsterminated27
2023-09-07P1/P2Teon Therapeutics, Inc.NCT05525455 TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)Advanced Cancer; Advanced Solid Tumor; Cancer; Oncologyterminated9
2023-09-07P2PharmasoftNCT06903156 Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)Primary Open-Angle Glaucoma (POAG)completed102
2023-09-08P1/P2AstraZeneca AZNNCT04630756 AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood CancerAdvanced Haematological Malignanciescompleted40
2023-09-08P2Merck Sharp & Dohme LLC MRKNCT04663321 Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)Treatment Resistant Depressionterminated99
2023-09-08 est.P2/P3Reistone Biopharma Company LimitedNCT04717310 Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic DermatitisAtopic Dermatitisunknown645
2023-09-08P3Harmony Biosciences Management, Inc. HRMYNCT05156047 A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic HypersomniaIdiopathic Hypersomniacompleted214
2023-09-08P1/P2Fusion Pharmaceuticals Inc. HTOONCT05363605 A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursAdvanced Solid Tumor; Head and Neck Squamous Cell Carcinoma; Bladder Carcinoma; Susceptible FGFR3 Geterminated6
2023-09-10 est.P3Sinovac Biotech (Colombia) S.A.S. SVANCT05433272 Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), InactivatedCOVID-19unknown1400
2023-09-11P3AstraZeneca AZNNCT03778957 A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional HepatocelHepatocellular Carcinomaactive not recruiting724
2023-09-11P3CSL BehringNCT04167514 Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids AloneGraft Versus Host Disease (GVHD)completed136
2023-09-11P3AbbVie ABBVNCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitiscompleted475
2023-09-11P2InterveXion Therapeutics, LLCNCT05034874 Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200Methamphetamine-dependence; Methamphetamine Abuseterminated61
2023-09-11P3Galderma R&DNCT05052983 A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo NodularisPrurigo Nodulariscompleted34
2023-09-11P2Eloxx Pharmaceuticals, Inc. ELOXNCT05448755 A Study of ELX-02 in Patients With Alport SyndromeAlport Syndromecompleted3
2023-09-11P3BioXcel Therapeutics Inc BTAIQNCT05665088 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)Agitation; Dementiaterminated13
2023-09-11P2Bial - Portela C S.A.NCT06597084 Anti-epileptogenic Effects of Eslicarbazepine AcetatePost Stroke Epilepsycompleted129
2023-09-12P1/P2Rocket Pharmaceuticals Inc. RCKTNCT03812263 A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-ILeukocyte Adhesion Defect - Type Icompleted9
2023-09-12P2Reneo Pharma LtdNCT04535609 An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy PatientsPrimary Mitochondrial Myopathycompleted213
2023-09-12P2Ocelot Bio, IncNCT05309200 A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney InjuryCirrhosis; Ascites; Hepatorenal Syndrome; Acute Kidney Injurycompleted47
2023-09-13P3Novartis Pharmaceuticals NVSNCT04181762 Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisLupus Nephritisterminated275
2023-09-13P3Gilead Sciences GILDNCT04313881 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)Myelodysplastic Syndromesterminated539
2023-09-13P2Pfizer PFENCT04707313 A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With ObesityObesitycompleted628
2023-09-13P2Keymed Biosciences Co.LtdNCT05186909 A Study of CM310 in Subjects With Moderate to Severe AsthmaAsthmacompleted52
2023-09-13P2Pfizer PFENCT05799495 A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not HospitalizedSARS-CoV-2 Infectioncompleted240
2023-09-14P2CelgeneNCT03257631 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain TumorsCentral Nervous System Neoplasms; Medulloblastomacompleted53
2023-09-14P3Jiangsu HengRui Medicine Co., Ltd.NCT04613674 A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Triple Negative Breast Cancercompleted441
2023-09-14P3Helixmith Co., Ltd.NCT04873232 A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral NeuropathyDiabetic Peripheral Neuropathycompleted106
2023-09-14P2Vaxcell Bio, Co., Ltd.NCT05040438 Natural Killer (NK) Cell Therapy in Locally Advanced HCCLocally Advanced Hepatocellular Carcinomacompleted17
2023-09-14P2BioCryst Pharmaceuticals BCRXNCT05116774 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyParoxysmal Nocturnal Hemoglobinuria (PNH)terminated12
2023-09-14P2Sanofi SNYNCT05179603 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Classic Hodgkin Lymphoma; Diffuse Large B-cell Lymphomaterminated14
2023-09-14P3Jiangsu Pacific Meinuoke Bio Pharmaceutical Co LtdNCT05813587 To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19Post-COVID-19completed121
2023-09-14P3ViiV HealthcareNCT05896748 Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With InHuman Immunodeficiency Virus Type 1 (HIV-1)completed94
2023-09-15P3Intercept PharmaceuticalsNCT02548351 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentNon Alcoholic Steatohepatitis (NASH)terminated2477
2023-09-15P3BayerNCT02626455 Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)Lymphoma, Non-Hodgkinterminated551
2023-09-15P1/P2ImmuneSensor Therapeutics Inc.NCT04020185 Safety and Efficacy Study of IMSA101 in Refractory MalignanciesSolid Tumor, Adultcompleted40
2023-09-15P3Novartis Pharmaceuticals NVSNCT04929249 A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic CardiovasculaAtherosclerotic Cardiovascular Diseasecompleted450
2023-09-15 est.P1/P2Shanghai Henlius BiotechNCT05102214 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancerunknown150
2023-09-15P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05549947 Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisModerate to Severe Atopic Dermatitiscompleted158
2023-09-15P3LianBio LLCNCT05629390 Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA StudyBlepharitiscompleted163
2023-09-15P2/P3Beijing Protgen Biotechnology Development Co., Ltd.NCT05858853 Phase II/III of Recombinant Human Serum AlbuminCirrhotic Ascitescompleted92
2023-09-15P2NFL Biosciences SASNCT06091826 Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)Smoking Cessation; Nicotine Dependencecompleted34
2023-09-15P3Catalysis SLNCT06361992 Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in ChildrenAtopic Dermatitis; Atopic Dermatitis and Related Conditions; Atopic Dermatitis Eczema; Atopic Dermatcompleted58
2023-09-18P2Merck Sharp & Dohme LLC MRKNCT02453594 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)Hodgkin Lymphomacompleted211
2023-09-18P2/P3Sun Pharmaceutical Industries LimitedNCT03552276 Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.Psoriatic Arthritiscompleted281
2023-09-18P2Imbria Pharmaceuticals, Inc.NCT04826185 A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy TrialNon-obstructive Hypertrophic Cardiomyopathycompleted67
2023-09-18P3LEO PharmaNCT04949841 Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 TrialsChronic Hand Eczemacompleted801
2023-09-18P3Rhythm Pharmaceuticals, Inc. RYTMNCT04966741 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityBardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesitycompleted12
2023-09-18P2BioCryst Pharmaceuticals BCRXNCT05116787 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyParoxysmal Nocturnal Hemoglobinuria (PNH)terminated12
2023-09-18P3Invex Therapeutics Ltd.NCT05347147 A Trial to Determine the Efficacy and Safety of Presendin in IIHIdiopathic Intracranial Hypertensionterminated14
2023-09-18P2Dompé Farmaceutici S.p.ANCT05368402 Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.Type 1 Diabetesterminated3
2023-09-18P2Xenon Pharmaceuticals Inc. XENENCT05376150 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderMajor Depressive Disordercompleted168
2023-09-18P3Bausch & Lomb Incorporated BLCONCT05815758 Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic SolutionAllergic Conjunctivitiscompleted512
2023-09-19P2/P3Humacyte, Inc. HUMANCT03005418 Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaTrauma; Vascular System Injurycompleted72
2023-09-19P2AstraZeneca AZNNCT03239340 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibEGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancercompleted154
2023-09-19P3AstraZeneca AZNNCT03961815 Open-label Extension Study of Brazikumab in Crohn's DiseaseCrohn's Disease; IBDterminated18
2023-09-19P2/P3Janssen Research & Development, LLCNCT04033445 A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisactive not recruiting1064
2023-09-19P2Novartis Pharmaceuticals NVSNCT04064242 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisPulmonary Sarcoidosiscompleted62
2023-09-19P3George Medicines PTY LimitedNCT04518306 Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of HypertensionHypertensioncompleted755
2023-09-19P3Sound Pharmaceuticals, Incorporated SOGPNCT04677972 SPI-1005 for the Treatment of Meniere's DiseaseMeniere Disease; Ménièrecompleted220
2023-09-19P1/P2Shanghai Antengene Corporation LimitedNCT04691141 A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)Myelodysplastic Syndrometerminated15
2023-09-19P3Biocon Biologics Inc.NCT05637515 Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis; Severe Chronic Plaque Psoriasiscompleted374
2023-09-20P3Janssen Research & Development, LLCNCT03170518 A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2completed171
2023-09-20P2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT03962543 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasPlexiform Neurofibroma; Neurofibromatosis Type 1 (NF1)active not recruiting114
2023-09-20P2Hoffmann-La RocheNCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive SquamousSquamous Cell Carcinoma of Head and Neckcompleted123
2023-09-20 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04956328 Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)Primary Biliary Cirrhosisunknown120
2023-09-20P2Novartis Pharmaceuticals NVSNCT05086744 Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersImmune Thrombocytopenia (ITP); Cold Agglutinin Disease (CAD)terminated19
2023-09-20P2Xalud Therapeutics, Inc.NCT05196919 Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis PainFacet Joint Pain; Back Pain; Inflammationcompleted75
2023-09-21P2Progenics Pharmaceuticals, Inc.NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Prostatic Neoplasm; Cancer of the completed120
2023-09-21P3Merck Sharp & Dohme LLC MRKNCT03976362 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNKCarcinoma, Squamous Cell, Non-small-cell Lungcompleted851
2023-09-21P1/P2NGM Biopharmaceuticals, IncNCT04068896 Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyPancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer; Melanoma; Non-smcompleted89
2023-09-21P2Imbria Pharmaceuticals, Inc.NCT04826172 Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-IIschemia; Coronary Artery Diseasecompleted58
2023-09-21P2Emerald Clinical Inc.NCT04974008 Osteosarcoma Maintenance Therapy With OST31-164Bone Canceractive not recruiting39
2023-09-21P1/P2NKGen Biotech, Inc.NCT05099549 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersSquamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Advaterminated11
2023-09-21 est.P2Pfizer PFENCT05545319 A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Coronavirus Disease 2019 (COVID-19); Iwithdrawn
2023-09-22P2Kite, A Gilead CompanyNCT02601313 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)Relapsed/Refractory Mantle Cell Lymphomacompleted105
2023-09-22P3Sanofi Pasteur, a Sanofi Company SNYNCT03537508 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants aHealthy Volunteers (Meningococcal Infection)completed2627
2023-09-22P2Juno Therapeutics, a Subsidiary of CelgeneNCT03744676 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OULymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neoplcompleted104
2023-09-22P3Sanofi SNYNCT04154956 SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-smallNon-small Cell Lung Cancer Metastaticterminated389
2023-09-22P2Novartis Pharmaceuticals NVSNCT04346654 A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITPImmune Thrombocytopenia (ITP)completed26
2023-09-22P2AstraZeneca AZNNCT04595370 Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseHeart Failure; Chronic Kidney Diseasecompleted153
2023-09-22P2Karyopharm Therapeutics Inc KPTIQNCT04768881 Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaLocally Advanced Unresectable or Metastatic Melanomaterminated15
2023-09-22P1/P2Hoffmann-La RocheNCT05116202 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)Melanomacompleted110
2023-09-22P2Shanghai Mabgeek Biotech.Co.LtdNCT05466877 A Study of MG-K10 in Subjects With Atopic DermatitisAtopic Dermatitisunknown163
2023-09-25P3BiotestNCT03444324 Adjusted Fibrinogen Replacement StrategyBleeding Disorder; Hypofibrinogenemia; Acquiredcompleted222
2023-09-25 est.P1/P2Immunocore Ltd IMCRNCT03973333 Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabSelect Advanced Solid Tumorswithdrawn
2023-09-25P2Ventyx Biosciences, IncNCT05655299 VTX958 Versus Placebo for the Treatment of Moderate to Severe PsoriasisPsoriasisterminated222
2023-09-26P2NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)NCT04314895 Trial of NanoPac Intratumoral Injection in Lung CancerLung Cancer, Nonsmall Cell; Lung Cancer; Lung Cancer, Small Cell; Neoplasm of Lungcompleted18
2023-09-26P2Novartis Pharmaceuticals NVSNCT04722666 Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in SubjectsMajor Depressive Disorder With Suicidal Ideation With Intentterminated199
2023-09-26P3ALK-Abelló A/SNCT04881461 A Study in Adults With Grass Pollen-induced RhinoconjunctivitisAllergycompleted445
2023-09-26P2BeiGeneNCT05116085 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal CancerColorectal Cancercompleted33
2023-09-27P3Hoffmann-La RocheNCT03452137 A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell CarciLocally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)terminated406
2023-09-27P1/P2Kartos Therapeutics, Inc.NCT04113616 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) orRelapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myelterminated70
2023-09-27P3Takeda TAKNCT05027308 A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or OlderShort Bowel Syndromecompleted3
2023-09-27P2Pfizer PFENCT05567952 A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19COVID-19completed436
2023-09-27P2Merck Sharp & Dohme LLC MRKNCT05602727 Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)Alzheimer's Diseaseterminated99
2023-09-27P1/P2Exscientia AI LimitedNCT05920408 Study to Assess EXS21546 in Combination in Patients With Advanced Solid TumoursAdvanced Solid Tumoursterminated6
2023-09-27P3AryoGen Pharmed Co.NCT06137092 rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic StudySevere Hemophilia Acompleted50
2023-09-28P3Bristol-Myers Squibb BMYNCT03138512 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove PCarcinoma, Renal Cellcompleted1641
2023-09-28P2CoImmuneNCT04203901 Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaAdvanced Renal Cell Carcinomaterminated16
2023-09-28P1/P2Spur TherapeuticsNCT04455230 A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190Fabry Disease; Lysosomal Storage Diseasesterminated3
2023-09-28P2OxurionNCT04527107 A Study to Evaluate THR-149 Treatment for Diabetic Macular OedemaDiabetes Mellitus; Diabetic Retinopathy; Diabetic Macular Edemacompleted135
2023-09-28P3Jazz Pharmaceuticals JAZZNCT05288283 Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresSeizures Associated With EMASterminated3
2023-09-28P2Altimmune, Inc. ALTNCT05295875 Efficacy and Safety of ALT-801 in the Treatment of ObesityObesity/Overweightcompleted391
2023-09-28P2Allgenesis Biotherapeutics Inc.NCT05301751 A Single Ascending Dose Cohort Study of AG-73305 in DME PatientsDiabetic Macular Edemacompleted25
2023-09-28P2Celldex Therapeutics CLDXNCT05368285 A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaChronic Spontaneous Urticariacompleted208
2023-09-28P1/P2Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.NCT05824455 A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid TumorsAdvanced Solid Tumorsterminated4
2023-09-28P1/P2Gan and Lee Pharmaceuticals, USANCT06256523 A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetescompleted72
2023-09-28P2Beijing Greatway Pharmaceutical Technology Co.,Ltd.NCT06796868 A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive DisorderMajor Depressive Disorder (MDD)completed280
2023-09-29P2/P3Hoffmann-La RocheNCT04191499 A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Breast Canceractive not recruiting325
2023-09-29P2CelgeneNCT04477850 A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate RiskMyelodysplastic Syndromescompleted30
2023-09-29P3ShionogiNCT04569084 Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSALSterminated384
2023-09-29P3ShionogiNCT05151471 Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALSALSterminated202
2023-09-29P2Longeveron Inc. LGVNNCT05233774 Lomecel-B Effects on Alzheimer's DiseaseMild Alzheimer's Diseasecompleted50
2023-09-29P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05257265 A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactivity Disordercompleted459
2023-09-29P3Mersana TherapeuticsNCT05329545 Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)High Grade Serous Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancerterminated20
2023-09-29P2Janssen Research & Development, LLCNCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasiscompleted227
2023-09-29P2Tonix Pharmaceuticals, Inc. TNXPNCT05686408 Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)Depression; Depressive Disorder; Depressive Symptoms; Depressive Disorder, Major; Depressive Episodecompleted132
2023-09-29P3Janssen Research & Development, LLCNCT05784129 A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical ResectionCrohn's Diseaseterminated4
2023-09-29P3Newsoara Biopharma Co., Ltd.NCT07712705 HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.Psoriasiscompleted515
2023-09-30 est.P2Viravaxx AGNCT03625934 Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001Hepatitis Bunknown84
2023-09-30P3BioVie Inc. BIVINCT04669028 A Phase 3 Study of NE3107 in Probable Alzheimer's DiseaseAlzheimer Diseasecompleted439
2023-09-30 est.P1/P2RaND Biosciences RANDNCT04733521 A Phase 1/2 Study of SC-43 in Combination With CisplatinAdvanced Non-small-cell Lung Cancer; Advanced Biliary Tract Cancerunknown100
2023-09-30 est.P3Biosolution Co., Ltd.NCT05051332 Phase 3 Clinical Trial of CartiLife® in KoreaArticular Cartilage Defect; Articular Cartilage Degenerationunknown104
2023-09-30 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05074602 A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal CandidiasisRecurrent Vulvovaginal Candidiasisunknown196
2023-09-30 est.P2Shanghai JMT-Bio Inc.NCT05132777 Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerLocally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutationsunknown155
2023-09-30 est.P2PT. Kimia Farma (Persero) TbkNCT05172193 Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)COVID-19unknown600
2023-09-30P1/P2Alaunos Therapeutics TCRTNCT05194735 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsGynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarciterminated8
2023-09-30 est.P2/P3ViriomNCT05204394 Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care TherapyHIV-1-infectionunknown438
2023-09-30 est.P3Mabwell (Shanghai) Bioscience Co., Ltd.NCT05324774 Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular EdemaDiabetic Macular Edemaunknown346
2023-09-30P3Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.NCT05577468 Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter PyloriHelicobacter Pylori Infectioncompleted561
2023-09-30 est.P3Synmosa Biopharma Corp.NCT05895877 Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic ConstipationConstipationunknown351

2023-10 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.